Tarnasky P R, Kovacs T O, Leung F W, Hirabayashi K, Jensen D M
Center for Ulcer Research and Education (CURE), VAMC-West Los Angeles.
Gastrointest Endosc. 1994 Jan-Feb;40(1):56-61. doi: 10.1016/s0016-5107(94)70010-9.
The aim of this study was to evaluate the effects of octreotide, a long-acting somatostatin analogue, on canine gastric mucosal blood flow and hemodynamics. We hypothesized that octreotide might decrease gastric mucosal blood flow without causing adverse hemodynamic effects. Two groups of dogs were anesthetized (six normal dogs and six dogs with prehepatic portal hypertension), and each dog was administered intravenous octreotide, normal saline solution, and vasopressin for 30 minutes on separate days in a blinded, randomized fashion. Vasopressin was included as treatment for a positive control. Gastric mucosal blood flow was assessed at the fundus, corpus, and antrum by endoscopic reflectance spectrophotometry. A femoral arterial catheter monitored systemic blood pressure and heart rate. Treatment responses for all observations were calculated for each dog as a percentage of baseline values. For mucosal blood flow, treatment responses did not differ significantly over time or between animal group or gastric location. Octreotide significantly decreased indices of hemoglobin concentration (-19%, p = 0.01) and oxygen saturation (-17%, p = 0.0002) compared to saline (-9% and -7%, respectively). The mean arterial pressure was increased after octreotide compared to saline (+23% versus +7%, p = 0.01), but octrotide had no effect on heart rate (+2% versus +1%). Vasopressin also decreased the indices of hemoglobin concentration (-34%) and oxygen saturation (-82%) significantly more than saline (p = 0.001). Vasopressin increased mean arterial pressure (+55%), but also caused reflex bradycardia (-22%) significantly more than saline (p = 0.001). We conclude that octreotide decreases canine gastric mucosal blood flow and appears to cause minimal hemodynamic changes.
本研究的目的是评估长效生长抑素类似物奥曲肽对犬胃黏膜血流和血流动力学的影响。我们假设奥曲肽可能会减少胃黏膜血流，而不会引起不良的血流动力学效应。两组犬只接受麻醉（六只正常犬和六只肝前性门静脉高压犬），每只犬在不同日期以盲法、随机方式静脉注射奥曲肽、生理盐水和血管加压素30分钟。血管加压素作为阳性对照治疗药物。通过内镜反射分光光度法评估胃底、胃体和胃窦的胃黏膜血流。股动脉导管监测全身血压和心率。计算每只犬所有观察指标的治疗反应，以基线值的百分比表示。对于黏膜血流，治疗反应在时间、动物组或胃位置之间没有显著差异。与生理盐水相比（分别为-9%和-7%），奥曲肽显著降低了血红蛋白浓度指标（-19%，p = 0.01）和氧饱和度（-17%，p = 0.0002）。与生理盐水相比，奥曲肽注射后平均动脉压升高（+23%对+7%，p = 0.01），但奥曲肽对心率没有影响（+2%对+1%）。血管加压素也显著降低了血红蛋白浓度指标（-34%）和氧饱和度（-82%），比生理盐水更明显（p = 0.001）。血管加压素增加了平均动脉压（+55%），但也导致反射性心动过缓（-22%），比生理盐水更明显（p = 0.001）。我们得出结论，奥曲肽可减少犬胃黏膜血流，且似乎引起最小的血流动力学变化。
